The Preliminary Clinical Application of Adoptive Immunotherapy with Auto-Cytokine Induced Killer Cells in the Patients with Malignant Solid Tumor

Objective To evaluate the ability to proliferate of cytokine-induced killer(CIK) cells cultured in autologous serum,and assess the safety and therapeutic effects of ex vivo therapeutic,which derived from Peripheral blood mononuclear cells(PBMCs) with the malignant solid tumor patients.Methods PBMC from 40 patients with malignant solid tumor were separated by fractionation on Ficoll-Hypaque gradient,and cultured in the RPMI-1640 medium containing 10% autologous serum,then were induced into CIK cells in the presence of Recombinant human interferonγ(rhIFN-γ),Recombinant human interleukin-2(rhIL-2) and anti-CD3mAb.Cell densities were determined on 13d,and the phenotypic patterns of CIK cells were characterized by flow cytometry,and cultured auto-CIK cells of incubation were transfused back to the patients.Results The number of CIK cells got obvious proliferation after 13d culture,increased to(30.0±5.2) fold,and the percentages of CD3~+and CD3~+CD16~+CD56~+ cells increased significantly to(93.0±6.1)%,(65.5±4.5)% and(25.8±12.2) %.After being treated with auto-CIK cells,6 patients were part cured;13 patients were make better;9 patients stoppedto develop and 12 patients were continuing growth.In general,the efficient level of this cure is 15%.Except temporal fever,chill fatigue,no severe side effects were observed during or after auto-CIK cells transfusion.Conclusion Our results indicated that CIK cells cultured in 10% autologous serum were expanded effectively,which derived from the patients with malignant solid tumor,then transfused therapy is safety and efficacy,and have few side effects.